Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
MediciNova Inc banner

MediciNova Inc
NASDAQ:MNOV

Watchlist Manager
MediciNova Inc Logo
MediciNova Inc
NASDAQ:MNOV
Watchlist
Price: 1.44 USD -2.7% Market Closed
Market Cap: $70.9m
Write Note Create Alert Ask AI

Wall St Price Targets

MNOV Price Targets Summary
MediciNova Inc

Wall Street analysts forecast MNOV stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MNOV is 9.18 USD with a low forecast of 6.06 USD and a high forecast of 11.55 USD.

MNOV Lowest Forecast
Wall Street Target
$6.06
321% Upside
MNOV Average Forecast
Wall Street Target
$9.18
538% Upside
MNOV Highest Forecast
Wall Street Target
$11.55
702% Upside
Lowest Forecast
Price Target
6.06 USD
321% Upside
Average Forecast
Price Target
9.18 USD
538% Upside
Highest Forecast
Price Target
11.55 USD
702% Upside
MediciNova Inc Competitors:
Price Targets
JACK
Jack in the Box Inc
4% Upside
8961
Mori Trust Sogo Reit Inc
9% Upside
LVO
LiveOne Inc
195% Upside
ACIU
AC Immune SA
235% Upside
JACK
Jack in the Box Inc
4% Upside
8961
Mori Trust Sogo Reit Inc
9% Upside
LVO
LiveOne Inc
195% Upside
ACIU
AC Immune SA
235% Upside

Revenue
Forecast

-5% / Year
Past Growth
142% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat
-5% / Year
Past Growth
142% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat

Over the last 13 years, the compound annual growth rate for Revenue has been -5%. The projected CAGR for the next 8 years is 142%.

What are analyst estimates?

Gross Profit
Forecast

-22% / Year
Past Growth
227% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
-22% / Year
Past Growth
227% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been -22%. The projected CAGR for the next 8 years is 227%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-11%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-11%
Average Miss

What are analyst estimates?

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-9%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-9%
Average Miss

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-14%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-14%
Average Miss

What are analyst estimates?

Continue MNOV Research

Summary
MNOV intrinsic value, competitors valuation, and company profile.
DCF Valuation
MNOV stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MNOV stock valuation using valuation multiples.
Wall St Estimates
MNOV price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MNOV stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other MediciNova Inc listings:
TSE • JPY
4875
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is MNOV's stock price target?
Price Target
9.18 USD

According to Wall Street analysts, the average 1-year price target for MNOV is 9.18 USD with a low forecast of 6.06 USD and a high forecast of 11.55 USD.

What is the Revenue forecast for MediciNova Inc?
Projected CAGR
142%

Over the last 13 years, the compound annual growth rate for Revenue has been -5%. The projected CAGR for the next 8 years is 142%.

What is the Gross Profit forecast for MediciNova Inc?
Projected CAGR
227%

Over the last 13 years, the compound annual growth rate for Gross Profit has been -22%. The projected CAGR for the next 8 years is 227%.

Back to Top
ALPHA SPREAD
Follow us
Join 355,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett